Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Resistance is futile: making drugs from bugs

30.03.2006
Antibiotic resistance is a major problem worldwide and there is an urgent need for new antibiotics to be developed. Potential new drugs are usually made in the lab which is complicated and time-consuming. An international team of scientists are using bacteria found naturally in the soil to produce new antibiotics in the fight against drug-resistant “Super-bugs” such as MRSA.

Led by Professor Tony Maxwell of the John Innes Centre (Norwich, UK) [1] and Professor Lutz Heide of the Pharmazeutisches Institut, Tübingen (Germany) [2], the team has developed ways of engineering harmless soil bacteria called Streptomyces to do the difficult chemistry for them. Streptomyces naturally make antibiotics to kill other bacteria in the soil. Unfortunately these don’t make very good drugs for use in humans because they are not very soluble in water and so cannot get into the bloodstream easily. The researchers have found a way to modify the bacteria to manufacture new varieties of these antibiotics that could be developed into more effective drugs. By studying variations of two natural antibiotics produced by Streptomyces, called novobiocin and clorobiocin, the scientists are determining which parts of the molecules are essential for their antibacterial activity. They hope that by varying other parts of the molecules they can design new antibiotics with better activity and fewer side effects.

Novobiocin and clorobiocin work by interfering with how DNA, the molecule that stores genetic information, is packed into the bacterial cell. The DNA in human cells is packed differently and so these cells are not affected by the antibiotics.

“This work is an excellent example of the European Union [3] at its best, combining the forces of seven labs from five different member states to carry out work that would not be possible by in lab working alone” said Tony Maxwell “We are very optimistic that we can make key discoveries about these antibiotics that will help them become vital weapons in our fight against MRSA and other bacterial infections”.

This exciting work is published this week in the journal Antimicrobial Agents and Chemotherapy [4] and will also be discussed at an event in Norwich as part of the BA Festival of Science in September 2006 [5].

Notes:

1.The John Innes Centre (JIC), Norwich, UK is an independent, world-leading research centre in plant and microbial sciences. The JIC has over 800 staff and students. JIC carries out high quality fundamental, strategic and applied research to understand how plants and microbes work at the molecular, cellular and genetic levels. The JIC also trains scientists and students, collaborates with many other research laboratories and communicates its science to end-users and the general public. www.jic.ac.uk. he JIC is grant-aided by the Biotechnology and Biological Sciences Research Council.

2.Pharmazeutisches Institut, Auf der Morgenstelle 8, D-72076 Tübingen, Germany. Tel.: +49 7071-29 72460

3.This work is published in the journal Antimicrobial Agents and Chemotherapy (Volume 50, issue 4) (Publishers: American Society for Microbiology).

4.This work was funded by a grant from the European Commission (Combigyrase LSHB-CT-2004-503466).

5.The BA (British Association for the Advancement of Science) Annual Festival of Science runs from 2nd-9th September 2006 in Norwich, and is the biggest public science event in the UK. It is expected to attract over 10,000 people from around the world with the theme of “People, Science and Society”.

Professor Tony Maxwell | alfa
Further information:
http://www.jic.ac.uk

More articles from Life Sciences:

nachricht Closing the carbon loop
08.12.2016 | University of Pittsburgh

nachricht Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>